We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Jeane
Guevara
jeane.guevara@rmh.nhs.uk
Prof
Vinidh
Paleri
Vinidh.Paleri@rmh.nhs.uk
Reyhaneh
SadeghZadeh
reyhaneh.sadeghzadeh@rmh.nhs.uk
Malignant neoplasms of lip, oral cavity and pharynx
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Squamous cell carcinoma (SCC) is a cancer that originates from the cells lining the body and can spread into the lymph glands and beyond. Some patients first present with an SCC which has moved to the lymph glands of the neck.
Clinical examination and imaging investigations are performed to try and identify the site where the cancer has originated. However, if no original site can be identified, then we call these ‘cancers of an unknown primary’ (CUP) of the head and neck.
One region where these cancers could have originated from is the oropharynx. There are two areas in the oropharynx were cancers commonly arise. One area is the palatine tonsils, which can be removed for analysis with an operation called tonsillectomy. The other area is the tissue lining the back of the tongue, known as the tongue base. A relatively new surgical technique called ‘tongue base mucosectomy’ (TBM) allows removal of this tissue to see if the primary cancer is contained within it. This study will then use a histological method called ‘step serial sectioning’ (SSS) to look in more detail at the tonsils and tongue base, hoping to increase the detection rate of the primary cancer.
Centres performing TBM will be asked to participate. Patients will be asked to consent to their tissue being used for SSS after it has undergone conventional histology. Anonymised samples will be sent to a central laboratory in Newcastle for processing. Other anonymised data regarding the patients' diagnosis and care will be collated. Patients will be asked to complete questionnaires regarding pain and swallowing recovery following surgery. A smaller cohort of patients will also be interviewed as part of a qualitative research process to establish their views on CUP and the acceptability of the above treatment.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Qualitative;
You can take part if:
You may not be able to take part if:
• Primary site identified by any means prior to being indicated for TBM • Patients undergoing targeted biopsies or resections
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
Vinidh
Paleri
Vinidh.Paleri@rmh.nhs.uk
Reyhaneh
SadeghZadeh
reyhaneh.sadeghzadeh@rmh.nhs.uk
Jeane
Guevara
jeane.guevara@rmh.nhs.uk
The study is sponsored by THE ROYAL MARSDEN NHS FOUNDATION TRUST and funded by ORACLE HEAD AND NECK CANCER UK LIMITED .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 44086
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
